Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab, Placebo, methotrexate (MTX); Drug · Other
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more

Conditions: Healthy
Interventions: DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Substance Use Disorders, Posttraumatic Stress Disorder, Opioid Use Disorder, Violence, Sexual, Violence, Gender-Based, Violence, Domestic
Interventions: Screening/Referral and Prevention; Behavioral
Lead sponsor: Clemson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Greenville, South Carolina

Conditions: Gestational Diabetes Mellitus
Interventions: Standard Glucola GCT, Twizzlers challenge; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more

Conditions: Urothelial Cancer
Interventions: Iza-bren, Cisplatin, Gemcitabine, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more

Conditions: Prostate Cancer
Interventions: zoledronate therapy, PET Scan; Drug · Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Farmington Hills, Michigan

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 30
States / cities: La Mesa, California • Lancaster, California • Mission Hills, California + 25 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, 68Ga-PSMA-11; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: HPPH; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: COVID
Interventions: Convalescent Plasma, Standard Donor Plasma; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Mental Stress, Emotional Stress
Interventions: TICM, TICO; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Childhood Obesity Prevention
Interventions: digital intervention + home visiting curriculum, Home visiting curriculum; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 16 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Adenoid Cystic Carcinoma
Interventions: Brontictuzumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Back Pain
Interventions: Kaia Back Pain App, Physiotherapist Exercise Instructions and written handouts; Other
Lead sponsor: Kaia Health Software; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myelodysplastic Syndrome
Interventions: Lenalidomide 50 mg, Lenalidomide 15 mg; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ofatumumab + Fresh Frozen Plasma; Drug
Lead sponsor: Joseph Tuscano; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Neurofibromatosis 1
Interventions: NF1 Educational Videos, Peer Navigator, Letters about NF1 Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo, Permitted DMARDs; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 156
States / cities: Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more

Conditions: Hematopoietic Neoplasms, Hematopoietic Malignancy
Interventions: STEPP Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 50
States / cities: Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more

Conditions: Esophageal Neoplasm
Interventions: UFT (Tegafur/Uracil); Drug
Lead sponsor: Edelman, Martin, M.D.; Individual
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Pharmatech Oncology; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 6
States / cities: Montgomery, Alabama • West Covina, California • Denver, Colorado + 2 more

Search by objective public record fields.

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders

Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Convalescent Plasma vs. Standard Plasma for COVID-19

Trauma Informed Care for Newly Resettled Refugees

Digitally Delivered Child Obesity Prevention for Parents in Home Visiting Programs

Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

Motion Coaching Technology for Physical Therapy in Low Back Pain.

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer